We are pleased to announce that Gregory Verdine, Ph.D., Erving Professor at Harvard University and Harvard Medical School Professor and serial entrepreneur, has joined WuXi Healthcare Ventures (WXHV) as newest Venture Partner.

Dr. Verdine has made numerous important contributions in the translation of bench science to the bedside and has founded, or co-founded, multiple successful biotechnology companies including: Enanta Pharmaceuticals (Nasdaq ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Pharmaceuticals (Nasdaq TKAI), WaVe Life Sciences (Nasdaq WVE), Eleven Biotherapeutics (Nasdaq EBIO), Warp Drive Bio, Aileron Therapeutics, and FogPharma.  He also co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.

Dr. Verdine is also a leading figure in the field of new therapeutic modalitie, and has developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug targets previously considered “undruggable”. Dr. Verdine holds a Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s University, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.

Dr. Verdine brings tremendous experience and expertise in life science research, new company formation and early stage operational management to WXHV and its portfolio companies developing innovative products.  His inspiration and past experience in cross-border activities between the U.S. and Asia suits WXHV’s investment strategy and need very well. We are honored to have Dr. Verdine join our growing team and we look forward to working together to develop transformative pharmaceutical solutions to the most vexing medical problems of our day.

 

Related articles:

  1. WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals
  2. WuXi Healthcare Ventures II Closes with Oversubscription